Treatment-refractory warts associated with fingolimod

Pract Neurol. 2022 Dec;22(6):503-504. doi: 10.1136/pn-2022-003477. Epub 2022 Aug 18.

Authors

Nitin Sahi¹, Sarmad A Al-Araji², Olga Ciccarelli², Declan T Chard^{2

3}, S Anand Trip^{2

3}

Affiliations

¹ Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK n.sahi@nhs.net.
² Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK.
³ University College London Hospitals (UCLH) Biomedical Research Centre, National Institute for Health Research (NIHR), London, UK.

PMID: 35981859
DOI: 10.1136/pn-2022-003477

No abstract available

Keywords: DERMATOLOGY; MULTIPLE SCLEROSIS.

MeSH terms

Fingolimod Hydrochloride / adverse effects
Humans
Immunosuppressive Agents / adverse effects
Multiple Sclerosis*
Multiple Sclerosis, Relapsing-Remitting* / diagnostic imaging
Multiple Sclerosis, Relapsing-Remitting* / drug therapy
Warts* / drug therapy

Substances

Fingolimod Hydrochloride
Immunosuppressive Agents